[Tolvaptan (Samsca) for the treatment of hyponatremia associated with the syndrome of inappropriate antidiuretic hormone secretion]

Comite d'Avaluacio de Medicaments d'Utilitzacio Hospitalaria (CAMUH)
Record ID 32010000710
Catalan
Authors' objectives:

To assess the efficacy, safety and efficiency of tolvaptan compared with any other treatment alternatives, including placebo, in adult patients with hyponatremia associated with SIADH.

Authors' recommendations: Tolvaptan quickly corrects blood sodium concentrations in patients with hyponatremia associated with CCI, cirrhosis and SIADH. Data in patients with SIADH that would indicate a greater impact of tolvaptan compared with patients with other etiologies are limited and stem from subgroup analyses. This is, however, the indication approved by the European Union. The benefits of tolvaptan in terms of symptom improvement in patients with hyponatremia have not been established.
Details
Project Status: Completed
Year Published: 2011
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Hyponatremia
  • Antidiuretic Hormone Receptor Antagonists
  • Tolvaptan
Contact
Organisation Name: Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address: Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name: direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email: direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright: <p>Catalan Agency for Health Technology Assessment and Research</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.